论文部分内容阅读
为探讨血浆血小板α-颗粒膜蛋白(GMP-140)在肝硬化患者血中变化的临床及病理生理意义,检测了40例肝硬化患者与31例健康对照者的血浆GMP-140水平和血小板计数。结果GMP-140水平肝硬化患者显著增高(P<0.01),且肝硬化Child B、C级患者均较Child A级患者显著升高(P<0.01),有上消化道出血者比无出血者亦明显增高(P<0.05);肝硬化患者GMP-140水平与血小板计数不相关(r=-0.0349,P>0.05)。结果表明肝硬化患者血浆GMP-140的升高可作为体内血小板活化及出血倾向的指标,并能反映肝功能状况。
In order to investigate the clinical and pathophysiological significance of plasma platelet α-granule membrane protein (GMP-140) in cirrhosis patients, the levels of plasma GMP-140 and platelet count in 40 cirrhotic patients and 31 healthy controls . Results The levels of serum GMP-140 in patients with cirrhosis were significantly higher (P <0.01), and those in Child B and C patients with cirrhosis were significantly higher than those in Child A patients (P <0.01) (P <0.05). The level of GMP-140 in patients with cirrhosis was not correlated with platelet count (r = -0.0349, P> 0.05). The results show that elevated plasma GMP-140 in patients with cirrhosis can be used as indicators of in vivo platelet activation and bleeding tendency, and can reflect the liver function status.